📊 LENZ Key Takeaways
Is LENZ Therapeutics, Inc. (LENZ) a Good Investment?
LENZ is a pre-profitability biotech company with severe operating losses ($44.1M) and deteriorating net income (-65% YoY) despite minimal revenue ($1.9M). With a cash burn rate of $33.6M annually against only $24.8M in cash, the company faces critical liquidity challenges within the next 9-12 months unless capital is raised. While the strong balance sheet ($246.5M equity, zero debt) provides some cushion, the company must demonstrate rapid revenue acceleration and expense management to avoid shareholder dilution through future funding rounds.
LENZ generates limited revenue with deeply negative operating and net margins, reflecting a heavy cash‑burn profile. Despite a debt‑free, equity‑rich balance sheet and strong current ratio, the ~$25M cash balance versus ~$69M annual operating outflows implies a short runway and likely external financing needs absent rapid fundamental improvement.
LENZ Therapeutics, Inc. Key Strengths (LENZ)
- Strong balance sheet with $246.5M stockholders equity and zero long-term debt
- Excellent liquidity position with 10.40x current ratio providing short-term financial flexibility
- Early revenue generation of $1.9M indicates commercialization has begun
- Debt-free capital structure with minimal liabilities
- Very strong current and quick ratios signaling near-term liquidity
- Large equity base relative to liabilities provides cushion
LENZ Stock Risks: LENZ Therapeutics, Inc. Investment Risks
- Severe cash burn rate of $33.6M annually against only $24.8M cash on hand creates less than 1-year runway
- Operating losses of $44.1M with net income deteriorating 65% YoY signal worsening financial trajectory
- Massive negative operating margin (-2321.7%) and minimal revenue indicate operations are not sustainable without continuous capital infusion
- Sustained operating losses and deeply negative free cash flow
- Cash balance insufficient relative to burn, raising dilution/financing risk
- Low revenue base with unclear gross margin and scalability
Key Metrics to Watch
- Quarterly revenue growth rate and path to profitability
- Monthly cash burn rate and updated cash runway estimate
- Operating expense trends, particularly R&D spending efficiency
- Regulatory approvals and clinical trial progress for product pipeline
- Additional capital raises and dilution impact on existing shareholders
- Quarterly operating cash flow vs. cash and equivalents (runway)
- Revenue growth and emergence of gross margin
LENZ Therapeutics, Inc. (LENZ) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 10.40x current ratio provides a solid financial cushion.
LENZ Profit Margin, ROE & Profitability Analysis
LENZ vs Healthcare Sector: How LENZ Therapeutics, Inc. Compares
How LENZ Therapeutics, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is LENZ Therapeutics, Inc. Stock Overvalued? LENZ Valuation Analysis 2026
Based on fundamental analysis, LENZ Therapeutics, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
LENZ Therapeutics, Inc. Balance Sheet: LENZ Debt, Cash & Liquidity
LENZ Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: LENZ Therapeutics, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-2.34 indicates the company is currently unprofitable.
LENZ Revenue Growth, EPS Growth & YoY Performance
LENZ Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | N/A | -$14.6M | $-0.53 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
LENZ Therapeutics, Inc. Dividends, Buybacks & Capital Allocation
LENZ SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for LENZ Therapeutics, Inc. (CIK: 0001815776)
📋 Recent SEC Filings
❓ Frequently Asked Questions about LENZ
What is the AI rating for LENZ?
LENZ Therapeutics, Inc. (LENZ) has a Combined AI Grade of C from Claude (C) and ChatGPT (C) with 72% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are LENZ's key strengths?
Claude: Strong balance sheet with $246.5M stockholders equity and zero long-term debt. Excellent liquidity position with 10.40x current ratio providing short-term financial flexibility. ChatGPT: Debt-free capital structure with minimal liabilities. Very strong current and quick ratios signaling near-term liquidity.
What are the risks of investing in LENZ?
Claude: Severe cash burn rate of $33.6M annually against only $24.8M cash on hand creates less than 1-year runway. Operating losses of $44.1M with net income deteriorating 65% YoY signal worsening financial trajectory. ChatGPT: Sustained operating losses and deeply negative free cash flow. Cash balance insufficient relative to burn, raising dilution/financing risk.
What is LENZ's revenue and growth?
LENZ Therapeutics, Inc. reported revenue of $1.9M.
Does LENZ pay dividends?
LENZ Therapeutics, Inc. does not currently pay dividends.
Where can I find LENZ SEC filings?
Official SEC filings for LENZ Therapeutics, Inc. (CIK: 0001815776) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is LENZ's EPS?
LENZ Therapeutics, Inc. has a diluted EPS of $-1.32.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is LENZ's fundamental grade?
Based on our AI fundamental analysis in June 2026, LENZ Therapeutics, Inc. has a C grade with 72% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is LENZ stock overvalued or undervalued?
Valuation metrics for LENZ: ROE of -16.8% (sector avg: 15%), net margin of -2,182.4% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is LENZ's AI grade for 2026?
Our dual AI analysis gives LENZ Therapeutics, Inc. a combined C grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is LENZ's free cash flow?
LENZ Therapeutics, Inc.'s operating cash flow is $-33.6M, with capital expenditures of $18.0K. FCF margin is -1,767.5%.
How does LENZ compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -2,182.4% (avg: 12%), ROE -16.8% (avg: 15%), current ratio 10.40 (avg: 2).